Editor's note: Our colleague Jeff Brown is well connected in biotech and government circles. During his recent research trip to the Pentagon, Jeff has learned about an unusual — and potentially highly lucrative — link between the U.S. military and a tiny biotech firm. We strongly encourage you to get the full story below... Dear Reader, For the past couple of years, I've been shadowing one of America's top biotech investors, Jeff Brown. I was worried Jeff was going to be just another ivory tower analyst. Boy, was I wrong! Sometimes I struggle to keep up with his packed schedule (and I'm half his age). One day he's in Boston, in a private meeting with biotech executives. Next, he's catching a flight to D.C. for an exclusive tour of the Pentagon. On yet another day, he's investing in the next billion-dollar tech startup. Jeff is a regular in places that are simply out of reach to most of us. And having him in your corner can be very lucrative. He was among the first to see the potential of CRISPR genetic editing. Two of his biotech recommendations soared 332% and 432% when the CRISPR story broke into the mainstream. In the last four years, Jeff also called the top performing stock on the S&P 500. Not once. Not twice. But three times. That's just scratching the surface. As an angel investor, he's currently sitting on biotech gains as high as 1,620% in his private portfolio. Whenever he gets excited about a new medical breakthrough, my ears perk up. I know it could mean big profits. Which brings me to today... Jeff just shared with me a high conviction opportunity linked to his recent Pentagon visit. In his research, Jeff learned the U.S. military — along with Google and Bill Gates — placed big bets on a tiny biotech company. It's no coincidence the FDA recently fast-tracked this company's new drug. It's set to be the biggest medical breakthrough in decades. A next generation antibiotic — the first of its kind since the 1980s. It's now almost ready to hit the market. The company is just waiting for the final go-ahead from the FDA. The announcement is due in the third quarter. Possibly as early as this month. Jeff believes shares of this tiny biotech could jump 12x in just hours when the big news breaks. These kinds of explosive opportunities don't come around very often. Especially in this volatile market. Jeff just recorded a special video about this biotech stock and how an FDA announcement in a few weeks could send it soaring. With his permission, I want to share it with you today. Click this link to watch it. Best of luck, Van Bryan
Managing Editor, Exponential Tech Investor | 
No comments:
Post a Comment